cloudfront

Report Detail



Pharma & HealthcareGlobal mRNA Vaccine Market Insights, Forecast to 2025

  • RnM2753637
  • |
  • 11 January, 2019
  • |
  • Global
  • |
  • 116 pages
  • |
  • QYResearch
  • |
  • Pharma & Healthcare

Global mRNA Vaccine Market Insights, Forecast to 2025

Table of Contents

    1 Study Coverage

    • 1.1 mRNA Vaccine Product
    • 1.2 Market Segments
    • 1.3 Key Manufacturers Covered
    • 1.4 Market by Type
      • 1.4.1 Global mRNA Vaccine Market Size Growth Rate by Product
      • 1.4.2 Standardization Of Cancer Treatment MRNA Vaccine
      • 1.4.3 Individualized Cancer Treatment MRNA Vaccine
      • 1.4.4 Infectious Disease Treatment MRNA Vaccine
      • 1.4.5 Infection Prevention MRNA Vaccine
    • 1.5 Market by End User
      • 1.5.1 Global mRNA Vaccine Market Size Growth Rate by End User
      • 1.5.2 Infectious Disease
      • 1.5.3 Cancer
      • 1.5.4 Other
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Executive Summary

    • 2.1 Global mRNA Vaccine Market Size
      • 2.1.1 Global mRNA Vaccine Revenue 2014-2025
      • 2.1.2 Global mRNA Vaccine Sales 2014-2025
    • 2.2 mRNA Vaccine Growth Rate by Regions
      • 2.2.1 Global mRNA Vaccine Sales by Regions
      • 2.2.2 Global mRNA Vaccine Revenue by Regions

    3 Breakdown Data by Manufacturers

    • 3.1 mRNA Vaccine Sales by Manufacturers
      • 3.1.1 mRNA Vaccine Sales by Manufacturers
      • 3.1.2 mRNA Vaccine Sales Market Share by Manufacturers
      • 3.1.3 Global mRNA Vaccine Market Concentration Ratio (CR5 and HHI)
    • 3.2 mRNA Vaccine Revenue by Manufacturers
      • 3.2.1 mRNA Vaccine Revenue by Manufacturers (2014-2019)
      • 3.2.2 mRNA Vaccine Revenue Share by Manufacturers (2014-2019)
    • 3.3 mRNA Vaccine Price by Manufacturers
    • 3.4 mRNA Vaccine Manufacturing Base Distribution, Product Types
      • 3.4.1 mRNA Vaccine Manufacturers Manufacturing Base Distribution, Headquarters
      • 3.4.2 Manufacturers mRNA Vaccine Product Type
      • 3.4.3 Date of International Manufacturers Enter into mRNA Vaccine Market
    • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Product

    • 4.1 Global mRNA Vaccine Sales by Product
    • 4.2 Global mRNA Vaccine Revenue by Product
    • 4.3 mRNA Vaccine Price by Product

    5 Breakdown Data by End User

    • 5.1 Overview
    • 5.2 Global mRNA Vaccine Breakdown Data by End User

    6 North America

    • 6.1 North America mRNA Vaccine by Countries
      • 6.1.1 North America mRNA Vaccine Sales by Countries
      • 6.1.2 North America mRNA Vaccine Revenue by Countries
      • 6.1.3 United States
      • 6.1.4 Canada
      • 6.1.5 Mexico
    • 6.2 North America mRNA Vaccine by Product
    • 6.3 North America mRNA Vaccine by End User

    7 Europe

    • 7.1 Europe mRNA Vaccine by Countries
      • 7.1.1 Europe mRNA Vaccine Sales by Countries
      • 7.1.2 Europe mRNA Vaccine Revenue by Countries
      • 7.1.3 Germany
      • 7.1.4 France
      • 7.1.5 UK
      • 7.1.6 Italy
      • 7.1.7 Russia
    • 7.2 Europe mRNA Vaccine by Product
    • 7.3 Europe mRNA Vaccine by End User

    8 Asia Pacific

    • 8.1 Asia Pacific mRNA Vaccine by Countries
      • 8.1.1 Asia Pacific mRNA Vaccine Sales by Countries
      • 8.1.2 Asia Pacific mRNA Vaccine Revenue by Countries
      • 8.1.3 China
      • 8.1.4 Japan
      • 8.1.5 Korea
      • 8.1.6 India
      • 8.1.7 Australia
      • 8.1.8 Indonesia
      • 8.1.9 Malaysia
      • 8.1.10 Philippines
      • 8.1.11 Thailand
      • 8.1.12 Vietnam
      • 8.1.13 Singapore
    • 8.2 Asia Pacific mRNA Vaccine by Product
    • 8.3 Asia Pacific mRNA Vaccine by End User

    9 Central & South America

    • 9.1 Central & South America mRNA Vaccine by Countries
      • 9.1.1 Central & South America mRNA Vaccine Sales by Countries
      • 9.1.2 Central & South America mRNA Vaccine Revenue by Countries
      • 9.1.3 Brazil
    • 9.2 Central & South America mRNA Vaccine by Product
    • 9.3 Central & South America mRNA Vaccine by End User

    10 Middle East and Africa

    • 10.1 Middle East and Africa mRNA Vaccine by Countries
      • 10.1.1 Middle East and Africa mRNA Vaccine Sales by Countries
      • 10.1.2 Middle East and Africa mRNA Vaccine Revenue by Countries
      • 10.1.3 GCC Countries
      • 10.1.4 Turkey
      • 10.1.5 Egypt
      • 10.1.6 South Africa
    • 10.2 Middle East and Africa mRNA Vaccine by Product
    • 10.3 Middle East and Africa mRNA Vaccine by End User

    11 Company Profiles

    • 11.1 Moderna Therapeutics
      • 11.1.1 Moderna Therapeutics Company Details
      • 11.1.2 Company Business Overview
      • 11.1.3 Moderna Therapeutics mRNA Vaccine Sales, Revenue and Gross Margin (2014-2019)
      • 11.1.4 Moderna Therapeutics mRNA Vaccine Products Offered
      • 11.1.5 Moderna Therapeutics Recent Development
    • 11.2 CureVac
      • 11.2.1 CureVac Company Details
      • 11.2.2 Company Business Overview
      • 11.2.3 CureVac mRNA Vaccine Sales, Revenue and Gross Margin (2014-2019)
      • 11.2.4 CureVac mRNA Vaccine Products Offered
      • 11.2.5 CureVac Recent Development
    • 11.3 Translate Bio
      • 11.3.1 Translate Bio Company Details
      • 11.3.2 Company Business Overview
    • 11.3.Translate Bio mRNA Vaccine Sales, Revenue and Gross Margin (2014-2019)
      • 11.3.4 Translate Bio mRNA Vaccine Products Offered
      • 11.3.5 Translate Bio Recent Development
    • 11.4 BioNTech
      • 11.4.1 BioNTech Company Details
      • 11.4.2 Company Business Overview
      • 11.4.3 BioNTech mRNA Vaccine Sales, Revenue and Gross Margin (2014-2019)
      • 11.4.4 BioNTech mRNA Vaccine Products Offered
      • 11.4.5 BioNTech Recent Development
    • 11.5 Sangamo Therapeutics
      • 11.5.1 Sangamo Therapeutics Company Details
      • 11.5.2 Company Business Overview
      • 11.5.3 Sangamo Therapeutics mRNA Vaccine Sales, Revenue and Gross Margin (2014-2019)
      • 11.5.4 Sangamo Therapeutics mRNA Vaccine Products Offered
      • 11.5.5 Sangamo Therapeutics Recent Development
    • 11.6 Argos Therapeutics
      • 11.6.1 Argos Therapeutics Company Details
      • 11.6.2 Company Business Overview
      • 11.6.3 Argos Therapeutics mRNA Vaccine Sales, Revenue and Gross Margin (2014-2019)
      • 11.6.4 Argos Therapeutics mRNA Vaccine Products Offered
      • 11.6.5 Argos Therapeutics Recent Development
    • 11.7 In-Cell-Art
      • 11.7.1 In-Cell-Art Company Details
      • 11.7.2 Company Business Overview
      • 11.7.3 In-Cell-Art mRNA Vaccine Sales, Revenue and Gross Margin (2014-2019)
      • 11.7.4 In-Cell-Art mRNA Vaccine Products Offered
      • 11.7.5 In-Cell-Art Recent Development
    • 11.8 eTheRNA
      • 11.8.1 eTheRNA Company Details
      • 11.8.2 Company Business Overview
      • 11.8.3 eTheRNA mRNA Vaccine Sales, Revenue and Gross Margin (2014-2019)
      • 11.8.4 eTheRNA mRNA Vaccine Products Offered
      • 11.8.5 eTheRNA Recent Development
    • 11.9 Ethris
      • 11.9.1 Ethris Company Details
      • 11.9.2 Company Business Overview
      • 11.9.3 Ethris mRNA Vaccine Sales, Revenue and Gross Margin (2014-2019)
      • 11.9.4 Ethris mRNA Vaccine Products Offered
      • 11.9.5 Ethris Recent Development
    • 11.10 Tiba Biotechnology
      • 11.10.1 Tiba Biotechnology Company Details
      • 11.10.2 Company Business Overview
      • 11.10.3 Tiba Biotechnology mRNA Vaccine Sales, Revenue and Gross Margin (2014-2019)
      • 11.10.4 Tiba Biotechnology mRNA Vaccine Products Offered
      • 11.10.5 Tiba Biotechnology Recent Development

    12 Future Forecast

    • 12.1 mRNA Vaccine Market Forecast by Regions
      • 12.1.1 Global mRNA Vaccine Sales Forecast by Regions 2019-2025
      • 12.1.2 Global mRNA Vaccine Revenue Forecast by Regions 2019-2025
    • 12.2 mRNA Vaccine Market Forecast by Product
      • 12.2.1 Global mRNA Vaccine Sales Forecast by Product 2019-2025
      • 12.2.2 Global mRNA Vaccine Revenue Forecast by Product 2019-2025
    • 12.3 mRNA Vaccine Market Forecast by End User
    • 12.4 North America mRNA Vaccine Forecast
    • 12.5 Europe mRNA Vaccine Forecast
    • 12.6 Asia Pacific mRNA Vaccine Forecast
    • 12.7 Central & South America mRNA Vaccine Forecast
    • 12.8 Middle East and Africa mRNA Vaccine Forecast

    13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

    • 13.1 Market Opportunities and Drivers
    • 13.2 Market Challenges
    • 13.3 Market Risks/Restraints
    • 13.4 Macroscopic Indicators

    14 Value Chain and Sales Channels Analysis

    • 14.1 Value Chain Analysis
    • 14.2 mRNA Vaccine Customers
    • 14.3 Sales Channels Analysis
      • 14.3.1 Sales Channels
      • 14.3.2 Distributors

    15 Research Findings and Conclusion

      16 Appendix

      • 16.1 Research Methodology
        • 16.1.1 Methodology/Research Approach
        • 16.1.2 Data Source
      • 16.2 Author Details

      mRNA is a rather versatile technology and offers a number of advantages. mRNA lacks genomic integration and its use results in transient expression of the encoded protein. This favorable safety profile makes mRNA especially attractive for vaccines and gene editing. mRNA is well defined chemically which ensures reproducible manufacturing at high yield, purity and activity. Improvements of lipid nanoparticle formulations as a vehicle for in vivo systemic delivery of mRNA has greatly favored the development of in vivo transfection strategies.
      The global mRNA Vaccine market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the mRNA Vaccine market based on company, product type, end user and key regions.

      This report studies the global market size of mRNA Vaccine in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of mRNA Vaccine in these regions.
      This research report categorizes the global mRNA Vaccine market by top players/brands, region, type and end user. This report also studies the global mRNA Vaccine market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

      The following manufacturers are covered in this report, with sales, revenue, market share for each company:
      Moderna Therapeutics
      CureVac
      Translate Bio
      BioNTech
      Sangamo Therapeutics
      Argos Therapeutics
      In-Cell-Art
      eTheRNA
      Ethris
      Tiba Biotechnology

      Market size by Product
      Standardization Of Cancer Treatment MRNA Vaccine
      Individualized Cancer Treatment MRNA Vaccine
      Infectious Disease Treatment MRNA Vaccine
      Infection Prevention MRNA Vaccine
      Market size by End User
      Infectious Disease
      Cancer
      Other

      Market size by Region
      North America
      United States
      Canada
      Mexico
      Asia-Pacific
      China
      India
      Japan
      South Korea
      Australia
      Indonesia
      Singapore
      Malaysia
      Philippines
      Thailand
      Vietnam
      Europe
      Germany
      France
      UK
      Italy
      Spain
      Russia
      Central & South America
      Brazil
      Rest of Central & South America
      Middle East & Africa
      GCC Countries
      Turkey
      Egypt
      South Africa

      The study objectives of this report are:
      To study and analyze the global mRNA Vaccine market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
      To understand the structure of mRNA Vaccine market by identifying its various subsegments.
      To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
      Focuses on the key global mRNA Vaccine companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
      To project the value and sales volume of mRNA Vaccine submarkets, with respect to key regions.
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

      In this study, the years considered to estimate the market size of mRNA Vaccine are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      This report includes the estimation of market size for value (million US$) and volume (K Doses). Both top-down and bottom-up approaches have been used to estimate and validate the market size of mRNA Vaccine market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.




      Summary:
      Get latest Market Research Reports on mRNA Vaccine . Industry analysis & Market Report on mRNA Vaccine is a syndicated market report, published as Global mRNA Vaccine Market Insights, Forecast to 2025. It is complete Research Study and Industry Analysis of mRNA Vaccine market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.


      REPORT YOU MIGHT BE INTERESTED

      Purchase this Report

      $3,900.00
      $5,850.00
      $7,800.00
      2,618.85
      3,928.28
      5,237.70
      3,588.78
      5,383.17
      7,177.56
      472,446.00
      708,669.00
      944,892.00
      258,622.26
      387,933.39
      517,244.52
      Add To Cart Credit card Logo

      Related Reports


      Reason to Buy

      Request for Sample of this report